220 related articles for article (PubMed ID: 3475525)
21. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B.
Liles D; Landen CN; Monroe DM; Lindley CM; Read MS; Roberts HR; Brinkhous KM
Thromb Haemost; 1997 May; 77(5):944-8. PubMed ID: 9184407
[TBL] [Abstract][Full Text] [Related]
22. [Preparation of rAAV2/hFIX and experimentally application to gene therapy for hemophilia B].
Peng JQ; Dong XY; Peng M; Chen L; Tan SP; Yuan H; Chen FP; Xue JL; Wu XB
Zhonghua Xue Ye Xue Za Zhi; 2004 Sep; 25(9):513-8. PubMed ID: 15569526
[TBL] [Abstract][Full Text] [Related]
23. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
[TBL] [Abstract][Full Text] [Related]
24. Biology of factor IX.
Kurachi K; Furukawa M; Yao SN; Kurachi S
Hematol Oncol Clin North Am; 1992 Oct; 6(5):991-7. PubMed ID: 1400083
[TBL] [Abstract][Full Text] [Related]
25. Primary myoblast-mediated gene transfer: persistent expression of human factor IX in mice.
Yao SN; Smith KJ; Kurachi K
Gene Ther; 1994 Mar; 1(2):99-107. PubMed ID: 7584074
[TBL] [Abstract][Full Text] [Related]
26. Complete deletion of factor IX gene and inhibition of factor IX activity in a labrador retriever with hemophilia B.
Brooks MB; Gu W; Ray K
J Am Vet Med Assoc; 1997 Dec; 211(11):1418-21. PubMed ID: 9394892
[TBL] [Abstract][Full Text] [Related]
27. Factor IX gene therapy for hemophilia.
Fewell JG
Methods Mol Biol; 2008; 423():375-82. PubMed ID: 18370215
[TBL] [Abstract][Full Text] [Related]
28. [In vitro expression of hemophilia B gene mediated by lentivirus].
Yan DM; Xu KL; Du B; Zeng LY; Lu QX; Pan XY
Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):583-6. PubMed ID: 19175982
[TBL] [Abstract][Full Text] [Related]
29. Persistent expression of canine factor IX in hemophilia B canines.
Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
[TBL] [Abstract][Full Text] [Related]
30. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
Fields PA; Kowalczyk DW; Arruda VR; Armstrong E; McCleland ML; Hagstrom JN; Pasi KJ; Ertl HC; Herzog RW; High KA
Mol Ther; 2000 Mar; 1(3):225-35. PubMed ID: 10933938
[TBL] [Abstract][Full Text] [Related]
31. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.
Wang L; Cao O; Swalm B; Dobrzynski E; Mingozzi F; Herzog RW
Gene Ther; 2005 Oct; 12(19):1453-64. PubMed ID: 15889137
[TBL] [Abstract][Full Text] [Related]
32. Gene therapy for hemophilia.
Chuah MK; Collen D; VandenDriessche T
J Gene Med; 2001; 3(1):3-20. PubMed ID: 11269333
[TBL] [Abstract][Full Text] [Related]
33. The carboxyl-terminal region of factor IX is essential for its secretion.
Kurachi S; Pantazatos DP; Kurachi K
Biochemistry; 1997 Apr; 36(14):4337-44. PubMed ID: 9100030
[TBL] [Abstract][Full Text] [Related]
34. Gene therapy for hemophilia: clinical trials and technical tribulations.
Viiala NO; Larsen SR; Rasko JE
Semin Thromb Hemost; 2009 Feb; 35(1):81-92. PubMed ID: 19308896
[TBL] [Abstract][Full Text] [Related]
35. Gene therapy of hemophilia B.
Kurachi K; Yao SN
Thromb Haemost; 1993 Jul; 70(1):193-7. PubMed ID: 8236102
[No Abstract] [Full Text] [Related]
36. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE
Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263
[TBL] [Abstract][Full Text] [Related]
37. Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells.
Wen J; Vargas AG; Ofosu FA; Hortelano G
J Gene Med; 2006 Mar; 8(3):362-9. PubMed ID: 16311997
[TBL] [Abstract][Full Text] [Related]
38. A factor IX gene probe: its use in carrier detection, antenatal diagnosis and characterisation of the molecular basis for hemophilia B.
Trent RJ; Svirklys L; Power PA; Rickard KA; Lammi A; Kronenberg H
Aust N Z J Med; 1985 Dec; 15(6):721-6. PubMed ID: 3869438
[TBL] [Abstract][Full Text] [Related]
39. Gene therapy for hemophilia.
Ponder KP
Curr Opin Hematol; 2006 Sep; 13(5):301-7. PubMed ID: 16888433
[TBL] [Abstract][Full Text] [Related]
40. Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX.
Bigger BW; Siapati EK; Mistry A; Waddington SN; Nivsarkar MS; Jacobs L; Perrett R; Holder MV; Ridler C; Kemball-Cook G; Ali RR; Forbes SJ; Coutelle C; Wright N; Alison M; Thrasher AJ; Bonnet D; Themis M
Gene Ther; 2006 Jan; 13(2):117-26. PubMed ID: 16163377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
